Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZN-B-2262 (Zion Pharma)
- Development stage
- Preclinical
- Lead developer
- Zion Pharma
- Modality
- Small Molecules
01
Overview
ZN-B-2262 (Zion Pharma): sourced facts only. name: "ZN-B-2262 exhibited strong inhibition against ATM with the IC50 at 4.4 nM." [DOI:10.1158/1538-7445.am2024-7127]; target: "ZN-B-2262 exhibited strong inhibition against ATM with the IC50 at 4.4 nM." [DOI:10.1158/1538-7445.am2024-7127]; developer: "1Zion Pharma Limited, Shanghai, China." [DOI:10.1158/1538-7445.am2024-7127]; modality: "ZN-B-2262 is a best-in-class, IND-approved, small molecule serine/threonine kinase receptor inhibitor targeting Ataxia Telangiectasia Mutated (ATM)" [DOI:10.1158/1538-7445.am2024-7127]; stage: "In the MDA-MB-468 xenograft efficacy study, ZN-B-2262 combined with a clinically relevant dose of DS-1062 showed significantly superior tumor inhibition effects compared to DS-1062 alone." [DOI:10.1158/1538-7445.am2024-7127]
02
Targets
ATM (Ataxia telangiectasia mutated protein)
Beyond the preview
Go deeper on ZN-B-2262 (Zion Pharma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZN-B-2262 (Zion Pharma).